Tranexamic Acid Product Launches For Gastrointestinal Bleeding

17 Aug 2017 11:53

Back to list of posts


Drug manufacturing companies are offering tranexamic acid for the treatment of acute gastrointestinal bleeding. Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma or surgery and is now finding applications for gastrointestinal diseases. Tranexamic acid reduces clot breakdown, thus reducing the duration and amount of bleeding. This reduces mortality rate (from 10% to 7.5%) and the probability of blood transfusion by about 30%. Major companies manufacturing tranexamic acid include Abbott Laboratories, Pfizer, GlaxoSmithKline and Bayer AG.


The Business Research Company expects the global gastrointestinal drugs market to grow from $52 billion in 2016 to $62 billion in 2020 at a compound annual growth rate (CAGR) of 4.5%. North America was the largest region in the gastrointestinal drugs market in 2016, accounting for $15 billion or 29.9% market share. This was mainly due to the high prevalence of obesity and digestive diseases due to unhealthy lifestyle in the North American countries. According to the National Center for Health Statistics, more than one-third (36.5%) of U.S adults were obese during 2011-2014.

Purchase the report at

The chart below shows the year-on-year growth of the global gastrointestinal drugs market during 2016-2020


According to The Business Research Company’s Healthcare and Biotechnology Consultant, Ravikiran, growing R&D activities for the development of new drugs in the treatment of gastrointestinal diseases is an emerging trend in the market. Some of the major gastrointestinal pipeline products include Perjeta (Roche), Keytruda (Merck), TAS-118 (Taiho Pharmaceutical), NeuVax (Galena Biopharma), Ipatasertib (Genentech), Durvalumab (AstraZeneca) and Napabucasin (Boston Biomedical). Technological advancements in the treatment of gastrointestinal diseases are expected to boost the market during the forecast period.

Request a sample of the report at

Takeda Pharmaceuticals was the largest competitor in the gastrointestinal diseases drugs market in 2016 with revenues of JPY 557.5 billion ($5.1 billion) in 2015. Takeda aims to harness new technologies and targeted treatments to develop innovative and new medicines for the treatment of gastrointestinal diseases. In 2014, the company launched ENTYVIO (vedolizumab), a gut-selective biologic for the treatment of ulcerative colitis and Crohn’s disease. Through specialized and strategic in-house development, external partnerships, in-licensing and acquisitions, Takeda also has a number of promising early-stage gastroenterology (GI) assets in development.

The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

This market is further classified as –
• Antacids
• Antiulcerants
• Antiobesity Antiemetics And Antinauseants
• Antidiarrhoeals

Pharmaceutical companies manufacturing drugs for gastrointestinal diseases initially involve in drug discovery process by which new drug candidates are discovered. This process includes identification of candidates, synthesis, characterization, screening and assays for therapeutic efficacy. Once the lead drug candidates are developed, they undergo preclinical trials in animals and filing for investigational new drug applications (IND) to initiate the clinical trials on humans. Preclinical trials may be conducted in-house or through a Contract Research Organization (CRO) that provides outsourced support to pharmaceutical companies. When the drug successfully passes all three phases of clinical trials, the CROs submit all their findings to the parent pharmaceutical companies which file new drug applications (NDA) in order to release the drug into the market.

Gastrointestinal Drugs Market Global Report 2017 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office the price is $6000 and $8000 if you wish to use across a multinational company.

About The Business Research Company

Visit, mail ofni.crbt|ofni#ofni.crbt|ofni or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.

The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.

It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.

The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations.

Comments: 0

Add a New Comment

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License